Comparison of oxaliplatin-related hepatic sinusoidal injuries in patients with gastric cancer who received S-1 or capecitabine as a combination chemotherapy

Abstract Comparison of oxaliplatin-related hepatic sinusoidal injuries in patients with gastric cancer who received S-1 or capecitabine as a combination chemotherapy Background: Oxaliplatin-based chemotherapy causes hepatic sinusoidal obstruction syndrome (SOS), resulting in portal hypertension with splenomegaly (SM). We herein aimed to compare the severity of hepatic SOS, and its impact on chemotherapy dose reduction or delay between two of the most commonly used oral fluoropyrimidines, S-1 and capecitabine, when combined with oxaliplatin in patients with gastric cancer. Methods: We analyzed patients from two prospective trials for gastric cancer, adjuvant XELOX (capecitabine 1000 mg/m2 bid on D1–14 + oxaliplatin 130 mg/m2 on D1 q3w, eight cycles; n = 52) and palliative SOX (S-1 40 mg/m2 bid on D1–14 + oxaliplatin 130 mg/m2 on D1 q3w, continuous [SOX-C, n = 52] vs. intermittent [SOX-I, discontinuing after 6th and restarting on progression, n = 53]). Spleen volume was measured using the Rapidia software. Results: Baseline sex, age, Eastern Cooperative Oncology Group Performance Status, platelet/liver enzyme/bilirubin levels, and spleen volume did not significantly differ between the XELOX and SOX-C groups. After the eight cycles, the SOX-C group showed more SM and hepatic parenchymal heterogeneity on CT scan and more severe hyperbilirubinemia and thrombocytopenia than the XELOX group. SM was significantly more associated with S-1 combination therapy (63.5% after eight cycles of SOX vs. 26.9% after the eight cycles XELOX; p < 0.001). The incidence of thrombocytopenia (≤ 100 × 103/μL) was significantly higher in SOX-C than in XELOX after six cycles (n = 20, 38.5% vs. n = 8, 15.4%; p = 0.008). In the SOX-C group, 209 of 1288 cycle treatments (16.2%) were delayed or reduced among 23 of 52 patients (44.2%) due to the thrombocytopenia and liver function test abnormalities, whereas in the XELOX group, only 28 of 832 cycles (3.3%) among four of 52 patients (7.6%) were delayed or reduced with same causes (p = 0.001). Conclusion: S-1 apparently worsens oxaliplatin-induced hepatic sinusoidal injuries more than capecitabine in gastric cancer patients. This could increase the incidences of splenomegaly, thrombocytopenia, bilirubin increase, and dose reduction or delay of chemotherapy.Maste

EDI Taxonomy 와 EDI 도입 전략

EDI(Electronic Data Interchange) has been used to automate the inter-organizational business transactions for a few decades. Originally it hired the OSI X.400 as its protocol and required separate private network, so called VAN. Nowadays Internet has expanded and been ubiquitous in the help of World Wide Web. At the same time, EDI has reached to adapt Internet technology for their network protocol. Therefore, today there are many technical forms to act EDI and each has suitable business trading environment. This paper deals with what EDI forms are suitable to what business trading environments. For this purpose, EDI technology has to be classified first, and the business situation should be examined. Proper choice of EDI technology to special business situation will help the competitive advantage in today’Ns threatening business environment

Fabrication method of colloidal crystals via confinedconvective assembly

본 발명은 미세 공간 대류 조립 방법을 이용한 콜로이드 결정의 제조방법에 관한 것으로 보다 상세하게는 두 기판 사이에 콜로이달 현탁액(colloidal suspension)을 주입하고, 모세관 힘에 의해 콜로이드 입자들이 자기 조립하여 기판상에 이차원(two-dimensional) 및/또는 삼차원(three-dimensional)의 콜로이드 결정을 제조하는 방법에 관한 것이다.본 발명은 콜로이드 현탁액의 용매를 제거함으로써 콜로이드 현탁액 용매의 제거에 따라 콜로이드 입자들을 메니스커스로 이동시키는 흐름(convective flow)을 조절할 수 있다. 이러한 콜로이드 입자들의 흐름조절로 인해 기존의 방법으로는 용이하지 않은 다양한 크기의 콜로이드 입자를 빠른 시간 내에 대면적의 이차원 콜로이드 결정 및/또는 삼차원 콜로이드 결정을 제조할 수 있다. 본 발명은 미세 공간 대류조립(Confined convective assembly) 방법을 이용하여 제조한 이차원 콜로이드 결정 및/또는 삼차원 콜로이드 결정을 바이오 센서 및 소자, 정보 저장 매체, 디스플레이 소자, 광학소자 등에 광범위하게 이용할 수 있다

용융삽입법을 이용한 신디오탁틱 폴리스티렌 나노복합체의 제조와 물성에 관한 연구

학위논문(석사) - 한국과학기술원 : 생명화학공학과, 2003.2, [ viii, 61 p. ]Polymer nanocomposite are particle-filled polymer where at least one dimension of the dispersed particle is on the nanometer scale. In this paper, syndiotactic polystyrene (sPS) / organophilic clay nanocomposite was fabricated by melt intercalation method. The fabrication method proper to high temperature processing of sPS was proposed and the microstructure and mechanical and thermal properties of fabricated nanocomposites were investigated. In chapter 2, we investigated the microstructure and materials properties of sPS / organophilic clay nanocomposites prepared by direct melt intercalation. In order to avoid the thermal instability problem of organophilic clay, we fabricated more thermally stable organophilic clay, which does not decompose at high processing temperature of sPS. Using the newly synthesized organophilic clay, we could fabrication sPS nanocomposite by direct melt intercalation. XRD and TEM results showed that this nanocomposite is an intercalated nanocomposite. From the non-isothermal crystallization, it is known that the overall crystallization rate of the nanocomposite slightly decreases with clay content. This result is related with the clay dispersion and physical hindrance of organic modifiers. And the growth of crystal seems to be hindered by the presence of clay layers. Nanocomposite showed the enhanced mechanical and thermal properties compared with the matrix polymer. In chapter 3, sPS nanocomposites prepared by stepwise melt intercalation was investigated. In this method, amorphous styrenic polymer was introduced to avoid the thermal instability problem of organophilic clay. Using poly(styrene-co-vinyloxazolin) (RPS) as amorphous styrenic polymer and thermally stable organophilic clay, we could fabrication sPS nanocomposite. XRD and TEM results showed that this nanocomposite has an exfoliated structure. The dispersion of clay layers of this system is better than that of nanocomposites prepared by direct melt intercalation. Previously...한국과학기술원 : 생명화학공학과